SK

Surender Kumar Singhal

Active Director Additional Director DIN 11430715
DIN 11430715 First appointment Jan 2026 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Jan 2026
Shareholding value β€’β€’β€’β€’ Premium profile

About Surender Kumar Singhal

Data last updated:

Surender Kumar Singhal is an Additional Director at Sios Pharmaceutical Private Limited (since 2026). The company operates in Pharma.

DIN 11430715
Primary Designation Additional Director
Industry Pharma
First Appointment 05 Jan 2026

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Sios Pharmaceutical Private Limited U33110DL2011PTC225960
Additional Director05 Jan 2026Active

Board colleagues of Surender Kumar Singhal

NameDINCompanyDesignation
Sushma Gupta03109874Sios Pharmaceutical Private LimitedDirector

Directorship timeline

Open interactive timeline →
Sios Pharmaceutical Private Limited
Premium access

Shareholding and investment profile for Surender Kumar Singhal

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Surender Kumar Singhal

Surender Kumar Singhal currently holds 1 directorship: Sios Pharmaceutical Private Limited (Additional Director, since 05 Jan 2026).

Surender Kumar Singhal was first appointed on 05 Jan 2026 as Additional Director at Sios Pharmaceutical Private Limited.

The current boards of Surender Kumar Singhal's companies include Sushma Gupta (Sios Pharmaceutical Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available